Skip to main content
. 2022 Apr 8;3(3):220–239. doi: 10.1158/2643-3230.BCD-21-0132

Figure 1.

Figure 1. DNMT3A-mutant HSCs are insensitive to the deleterious Effects of IFNγ in vivo. A, Schematic of competitive transplant where recipients were challenged with IFNγ. B, Number of donor-derived HSCs (CD45.2+Lineage−c-Kit+EPCR+CD48−CD150+) in BM of recipients 18 weeks post primary transplant (n = 8–15). C, Quantification of donor-derived HSCs in BM of recipients 18 weeks post secondary transplant (n = 3–5). D, Schematic of transplantation of CRISPR-edited human CD34+ cord blood cells into NSG mice. E, Number of human HSCs (mCD45−hCD45+Lineage−CD38−CD34+CD45RA−CD90+CD49f+) in BM of NSG recipients 18 weeks post-transplant (n = 5–9). F, Number of human HSCs in BM of NSG recipients 18 weeks postsecondary transplant (n = 2–4). G, Relative clone size of CRISPR-edited human cells postsecondary transplant (hCD45+ BM). VAF post secondary transplant was normalized to that of pretransplant CD34+ cells. One-way ANOVA; *, P < 0.05; **, P < 0.01. Data represent mean ± SEM.

DNMT3A-mutant HSCs are insensitive to the deleterious effects of IFNγ in vivo. A, Schematic of competitive transplant where recipients were challenged with IFNγ. B, Number of donor-derived HSCs (CD45.2+Lineage−c-Kit+EPCR+CD48−CD150+) in BM of recipients 18 weeks postprimary transplant (n = 8–15). C, Quantification of donor-derived HSCs in BM of recipients 18 weeks postsecondary transplant (n = 3–5). D, Schematic of transplantation of CRISPR-edited human CD34+ cord blood cells into NSG mice. E, Number of human HSCs (mCD45−hCD45+Lineage−CD38−CD34+CD45RA−CD90+CD49f+) in BM of NSG recipients 18 weeks posttransplant (n = 5–9). F, Number of human HSCs in BM of NSG recipients 18 weeks postsecondary transplant (n = 2–4). G, Relative clone size of CRISPR-edited human cells postsecondary transplant (hCD45+ BM). VAF postsecondary transplant was normalized to that of pretransplant CD34+ cells. One-way ANOVA; *, P < 0.05; **, P < 0.01. Data represent mean ± SEM.